To elucidate the fundamental actions of en dogenous opioids and naloxone on the cerebral circula tion, the effects of (0-Met2,Pr05)-enkephalinamide and naloxone on pial vessels were investigated in cats, Pial arteries (165.7 ± 24.9 /-Lm) were found to dilate after the intravenous administration of 1 mg/kg of (0-Met2,Pro5) enkephalinamide, and a definite dilatation of 7. 1-7.6% persisted for 15 min. Pial veins (100.6 ± 20,2 /-Lm) also dilated but to a lesser degree. The MABP (1 18.7 ± 10.5 mm Hg) decreased by 20 mm Hg immediately after the injection, but gradually returned to the initial value 15 min later, The observed cerebral vasodilatation may be attributable to sympathetic inhibition mediated either by the presynaptic opiate receptors of the cerebral vessels 34 or by the opiate receptors in the brainstem, After the intravenous administration of I mg/kg of naloxone, pial arteries (122.0 ± 17.2 /-Lm) showed a slight but significant dilatation of 2.3-5.3%. There were no significant changes in pial veins (87.0 ± 12.4 /-Lm). MABP (130.4 ± 12,3 mm Hg) was slightly increased after the injection. Although the mechanism involved was unclear, the cerebral vaso dilatation occurring after the administration of naloxone may contribute to its ameliorating effect on the neurolog ical symptoms following cerebral ischemia, Key Words: Cranial window -(0-Met2 ,Pro5)_ Enkephalinamide-N al oxone-Opiate receptor-Pial vessel-Sympathetic in hibition,
Various polypeptides, such as substance P (Ed vinsson et aI., 1981) and vasoactive intestinal poly peptide (Larsson et aL, 1976) , have been shown to exist and to function as neurotransmitters or neu romodulators in cerebral vessels, Enkephalins are endogenous opioid pentapeptides, identified by Hughes et aI. in 1975. They are widely distributed throughout the central nervous system (Elde et aL, 1976; Simantov et aL, 1977) , and have also been shown to pass through the blood-brain barrier (Kastin et aI., 1976; Rapoport et aL, 1980) .
Recently, Baskin and Hosobuchi (I 98 I) and Ho sobuchi et aI. (1982) observed a transient elimina tion of neurological deficits caused by cerebral isch emia following the intravenous administration of naloxone, a potent opioid antagonist, and exacer bation of the symptoms after morphine injection, Since they implicated a pathophysiological role for endogenous opioids in cerebral ischemia, the basic mechanisms by which such endogenous opioids or antagonists exert their effects are a matter of in terest. There have been several reports on the ef fects of naloxone and other opioid antagonists on the cerebral circulation and metabolism under normal or ischemic conditions (Takeshita et aI., 1972; Faden et aL, 1982; Grandison et aI., 1982; Levy et aI., 1982; Safo et al., 1983; Shigeno et aI., 1983) , but the results were not uniform. On the other hand, only a few investigators have examined the effects of opioid peptides on cerebral vessels (Hanko and Hardebo, 1978; Wahl, 1982; Sandor et al., 1983) and metabolism (Sakurada et al., 1978) .
To determine the fundamental actions of enkeph alins and naloxone on the cerebral hemodynamics, we investigated the effects of the stable synthetic enkephalin analog (D-Met 2 ,Pro5)-enkephalinamide (Szekely et al., 1977; R6nai et al., 1981) and nal oxone on the caliber of pial vessels under normal conditions in anesthetized cats, using a video camera method (Okayasu et aI., 1979; Gotoh et aI., 1982) .
MATERIALS AND METHODS
Eleven adult cats of either sex weighing 2.3-3.3 kg were anesthetized by the intraperitoneal injection of Ci chloralose (50 mg/kg) and urethane (500 mg/kg). Fol lowing tracheotomy and endotracheal intubation, the an imals were ventilated with a respirator (model 662; Har vard). Small doses of aIcuronium chloride were given when necessary. Polyethylene catheters were inserted into both femoral arteries and used for monitoring the systemic arterial blood pressure with a pressure trans ducer (Statham P23 ID) and for sampling arterial blood for blood gas analysis (BMS3 Mk2 Blood Micro System; Radiometer). One femoral vein was cannulated with a polyethylene catheter, which was used for administration of drugs. The cranium of the animals was fixed in a ste reotaxic headholder (type SN-1; Narishige), and the scalp was reflected at the midline. A burr hole of I cm in di ameter was trephined in the right parietal region of the skull, and the dura was incised and reflected carefully. A cranial window was tightly screwed into the burr hole. The space beneath the cranial window was filled with artificial cerebrospinal fluid having a composition of N a + 152.5 mEq/L, K + 2.9 mEq/L, Cl-140.0 mEq/L, Ca2+ 5.2 mEq/L, Pi 1.7 mEq/L, Mg2+ 1.9 mEq/L, HC03 -20.8 mEq/L, glucose 0.05%, and pH 7.40. The rectal temper ature of the animals was maintained at 37-37SC using a heating blanket.
Measurement of the pial vessel diameter was accom plished by employing the video camera method devel oped in our laboratory. The details of the method have been reported elsewhere (Okayasu et ai., 1979; Gotoh et aI., 1982) . In short, through a video camera, images of pial vessels were visualized on a television monitor. The diameters of three selected target vessels were measured simultaneously and continuously by the width analyzers, and recorded on a multichannel recorder (model PG-6; Rikadenki). The resolution of the system was 1.98 ILm at x 200 magnification; the reproducibility was >99%; and the response time for 100% change was <0.8 s. The sta bility of recording was extremely high, and the baseline shift was negligible for 4-5 h (Okayasu et al., 1979) .
In six cats, I mg/kg of (o-Met2,Pro5)-enkephalinamide was injected intravenously, and in another five cats, I mg/ kg of naloxone hydrochloride was injected intravenously. The diameters of two pial arteries and one pial vein in each cat were recorded in steady-state conditions and for 15 min after the administration of each drug. Statistical analysis was performed by Student's t test and Wilcox on's signed rank test. Figure 1 shows representative recordings of the diameters of the pial arteries and vein and systemic arterial blood pressure before and after the intra venous injection of (D-Met 2 ,Pro5)-enkephalinamide. Clearly, the pial arteries and vein dilated immedi ately after administration of the drug, and their di latation persisted during the period of observation. The arterial blood pressure fell markedly after ad ministration of the agent, although it did tend to recov.er gradually. Figure 2 summarizes the time course of changes in the pial arterial diameter, pial venous diameter, and MABP after the intravenous administration of 1 mg/kg of (D-Met 2 ,Pr05)-enkephalinamide. Since there was no difference in reaction between the small and large arteries, analysis of them was per formed together. The pial arterial diameter (165.7 ± 24.9 /-Lm) increased immediately after injection of the drug, and a definite dilatation of 7.1-7.6% persisted for 15 min. The pial venous diameter 000.6 ± 20.2 /-Lm) followed the changes in pial ar terial diameter but to a lesser degree. MABP was 118.7 ± 10.5 mm Hg initially, and showed a rapid decrease to 96.0 ± 14.7 mm Hg after injection of the agent. Subsequently, it increased gradually and returned to the initial value (118.0 ± 11.6 mm Hg) 15 min after the administration.
RESULTS
An example of continuous recordings of the di- ameter of the pial arteries and vein and systemic arterial blood pressure before and after the intra venous administration of naloxone is presented in Fig. 3 . The pial arteries underwent a gradual dila tation after injection of the agent, whereas the cal iber of the pial vein remained unchanged. The ar terial blood pressure showed minimal elevation. Mean values for the pial arterial diameter, pial venous diameter, and MABP following the intra venous injection of 1 mg/kg of naloxone are given in Fig. 4 . The pial arteries (122. 0 ± 17.2 fJ.-m)
showed a slight but significant increase in diameter of 2.3-5.3% throughout the period of observation. The pial venous diameter (87.0 ± 12. 4 fJ.-m) under went a small decrease after administration of the agent, but the change was not statistically signifi cant. MABP (130.4 ± 12.3 mm Hg) was elevated to a small extent after injection of the drug. There were no alterations in arterial Peo 2 , Po 2 , or pH par allel to the changes in vessel diameters.
DISCUSSION
(D-Met 2 ,Pro5)-Enkephalinamide is a stable syn thetic enkephalin analog that exerts a potent anal gesic action when given intravenously or intraven tricularly, and its effects are readily reversed by nal oxone (Szekely et aI., 1977; R6nai et aI., 1981) . In our experiments, the pial arteries dilated immedi ately after the intravenous administration of (D Met 2 ,Pr05)-enkephalinamide, and a definite dilata tion of 7 -8% lasted for at least 15 min during the observation period. The vasodilatation was also ac companied by a decrease in MABP of 20 mm Hg at maximum. Since it is well known that the pial arteries dilate along with a reduction in systemic arterial blood pressure under physiological condi tions (Fog, 1937; Gotoh et aI., 1975) , it is possible that the observed vasodilatation reflects merely the normal autoregulatory response to a fall in MABP. Gotoh et aI. (1981) have previously reported, how ever, that the pial artery diameter showed "mirror image" changes to the changes in systemic arterial blood pressure during hemorrhagic hypotension. As clearly demonstrated in Fig. 2 , this was not the case in the present experiment; further, the dilatation of the pial arteries persisted even after restoration of the MABP to the initial value at 15 min after ad ministration of the agent. These findings suggest that the vasodilatation following (0-Met2 ,Pr05)-en kephalinamide administration was not simply a sec ondary response of the vessels to the fall in sys temic arterial blood pressure.
There have been few investigations on the effects of endogenous opioids on cerebral vessels, and the results are far from consistent. Hanko and Hardebo (1978) found that dissected middle cerebral arteries of cats, preconstricted with prostaglandin F 2 cr , showed a dilatation after the administration of Met and Leu-enkephalin, and the effect was blocked by naloxone. On this basis, they assumed the existence of smooth muscle or postsynaptic opiate receptors in the feline pial arteries. Wahl (1982) observed no significant changes in pial arterial dimensions by the direct application of Leu-enkephalin, (0-Ala2)-Met enkephalinamide, or morphine to the pial arteries of cats in vivo over a concentration range of 10-10 to 10-4 M. Although slight but significant vasodi latations were observed at a higher concentration, he ascribed them to nonspecific effects of the drugs. On the other hand, Sandor et al. (1983) demon strated a significant fall in cortical blood flow and tissue P0 2 in vivo following the topical administra tion of Met -enkephalin (from 10 -7 to 5 x 10 -6 M) to the brain surface in awake cats.
Several authors have assumed the existence of inhibitory presynaptic opiate receptors, which differ from the presynaptic a-adrenoceptors, based on the fact that morphine, Met-enkephalin, Leu-enkephalin, and l3-endorphin inhibit both the re lease of noradrenaline and the contraction of the nictitating membrane elicited by nerve stimulation in cats (Henderson et aI., 1975; Dubocovich and Langer, 1980) . Furthermore, the vasoconstrictive response of the rabbit ear artery to electric nerve stimulation was found to be inhibited by the admin istration of Met-enkephalin methylester and of Leu enkephalin. On this basis, Knoll (1976) inferred the existence of presynaptic enkephalin receptors for the regulation of neurotransmitter release in the rabbit ear artery. (0-Met2 ,Pr05)-Enkephalinamide has also been reported to prevent the constriction of the rabbit ear artery provoked by nerve stimulation (R6nai et aI., 1981) . The physiological role of the sympathetic nerves in the regulation of cerebral vascular tone is a matter of dispute (Edvinsson and MacKenzie, 1977; Kuschinsky and Wahl, 1978) . Heistad et al. (1978) found by the microsphere tech nique that sympathetic tone in relation to cerebral vessels was minimal in dogs, cats, and monkeys. However, using a cranial window method, we ob served dilatation of the pial arteries following the administration of 5-hydroxydopamine (a false neu rotransmitter) and fusaric acid (dopamine-l3-hy droxylase inhibitor) under experimental conditions including a-chloralose and urethane anesthesia in cats, and suggested the importance of sympathetic nerves in the maintenance of normal cerebral vas cular tone (Fukuuchi et aI., 1979; Gotoh et aI., 1981) . It seems probable, therefore, that the dila tation of the pial arteries observed after the sys temic administration of (0-Met2 ,Pro5)-enkephalin amide was caused by inhibition of noradrenaline release or by sympathetic inhibition mediated by the presynaptic opiate receptors of the pial arteries.
Endogenous and synthetic opioids have been re ported to decrease the sympathetic tone and to in crease the vagal tone by exerting a central action on the medulla oblongata (Laubie et aI., 1974 (Laubie et aI., , 1977 Bolme et aI., 1978) , which may contribute to the hypotension and bradycardia observed after the ad ministration of opioids. Opiate receptors (Atweh and Kuhar, 1977) and endogenous opioids (Elde et aI., 1976; Simantov et aI., 1977) exist abundantly in some of the structures related to cardiovascular control in the brainstem. Moreover, enkephalin is suggested to inhibit the transmitter release presyn aptically from noradrenergic nerve terminals in the cerebral cortex (Taube et aI., 1976) , and l3-endor phin to regulate neurotransmitter release through the inhibition of calcium influx (Guerrero-Munoz et aI., 1979) . Since the pial vessels are richly inner vated with noradrenergic fibers of sympathetic or Igm, which may manifest themselves through the maintenance of vascular tone (Edvinsson and MacKenzie, 1977; Gotoh et aI., 1981) , the other possibility exists that the observed dilatation of the pial arteries was caused by central sympathetic in hibition with opioid peptides. Clonidine, a potent <xz-adrenoceptor agonist, also exhibits an action on the cerebral vessels through central inhibition of sympathetic activity (Kobari, 1983) , but inhibitory opiate receptors and <xz-adrenoceptors appear to be different (Laubie et aI., 1974; Taube et aI., 1976; Dubocovich and Langer, 1980) . Although it is not possible at present to conclude which opiate recep tors, i.e., peripheral presynaptic or central, partic ipate mainly in the dilatation of the pial arteries, inhibition of the sympathetic nerves seems to be involved in the mechanisms.
Following the intravenous administration of nal oxone, the pial arteries showed a slight but signifi cant dilatation that persisted for 15 min (Fig. 4) . The arterial dilatation was accompanied by a small in crease in systemic arterial blood pressure, but since normal vasoconstrictive responses to elevation of blood pressure were preserved in two of three ani mals examined, the dilatation of the pial arteries could not be ascribed to the changes in blood pres sure. Brandt et al. (1983) recently reported that the relaxation of human pial arteries by N alonee in vivo was attributable not to naloxone itself but to the preservatives in the Nalonee preparation. Since we employed pure naloxone without any preservatives, the observed dilatation of the pial arteries was prob ably due to naloxone itself. The fact that both the opiate agonist (D-MetZ ,Pro5)-enkephalinamide and antagonist naloxone caused dilatation of pial ar teries in our experiments might be explained by as suming a nonspecific action of naloxone on the pial arteries that is unrelated to its effect on opiate re ceptors. Pharmacological actions of naloxone un related to opiate receptor blockade have recently been noted by several investigators (Sawynok et aI., 1979) . These include, for example, lipid antioxidant properties (Kon!h et aI., 1981) , the inhibition of pro teolysis and stabilization of lysosomal membranes (Curtis and Lefer, 1980) , and an influence on the glycogen phosphorylase activity (Shigeno et aI., 1983) . Unfortunately, no data are yet available to suggest the intervention of non-opiate receptor-me diated actions of naloxone on the cerebral vessels, and the precise mechanisms of pial arterial dilata tion after the administration of naloxone still remain unknown. However, the direct vasodilatory action of naloxone may be related to its ameliorating effect on the neurological symptoms after cerebral isch emia.
In conclusion, the pial arteries were dilated after J Cereb Blood Flow Metabol, Vol. 5, No. 1, 1985 the systemic administration of (D-MetZ ,Pro5)-enkeph alinamide (1 mg/kg) in cats. This appeared to be mediated by sympathetic inhibition either at the pe ripheral presynaptic opiate receptors of the cerebral vessels or at the central opiate receptors in the brainstem. The intravenous injection of naloxone (1 mg/kg) was also followed by a dilatation of the pial arteries, but the mechanism involved was unclear. Further investigations are now in progress to clarify the precise mechanisms of action of endogenous opioids on the cerebral vessels, using new methods.
